EAGER: Complete 3D imaging of needle biopsy to diagnose pancreatic cancer

1212540 Seibel提出了一种对含有胰腺癌的切除组织（动物和人）进行细针芯活检（TNCB）的处理和成像的新方法。直径为0.25 mm的TNCB样本将通过定制设计的取芯装置获得，而更大的0.40 mm芯将使用新的商业活检针获得。将在TNCB采样点或其旁边采集相应的细针穿刺（FNA）标本。在将TNCB组织保持在试管或微流体室内的同时，将对样本进行固定、染色和光学透明。苏木素和伊红（HE）吸收染料将为细胞和组织的形态结构提供透射图像对比;荧光染料将从各种免疫组织学靶点成像，例如在基底上皮膜上表达的蛋白质，以帮助确定侵袭和蛋白质表达。光学投影断层显微镜（OPTM）将用于生成活检组织的3D多模态图像。尽管组织核心的长度将比显微镜视场（FOV）长，但是组织的不同区域将通过图像处理成像并缝合在一起。将使用定制计算机界面向病理学家提供整个TNCB标本的2D和3D可视化，以操作3D数据集。将使用组织切片病理学作为金标准来进行癌症诊断的灵敏度和特异性。将对使用OPTM与传统FNA成像的TNCB进行胰腺癌诊断的比较评价。这项新技术不仅有望检测肿瘤细胞的存在，还有望检测癌细胞对组织的侵袭。

1212540SeibelA new method for processing and imaging of thin-needle core biopsy (TNCB) of resected tissue containing pancreatic cancer (animal and human) is proposed. TNCB specimens of 0.25mm diameter will be obtained by a custom-designed coring device, while larger 0.40mm cores will be taken with a new commercial biopsy needle. Corresponding fine needle aspirate (FNA) specimens will be taken at or alongside the TNCB sample sites. While maintaining TNCB tissue within a tube or microfluidic chamber, the specimen will be fixed, stained, and optically cleared. Absorption dyes of hematoxylin and eosin (H&E) will provide transmission image contrast for the morphological structure of cells and tissue.Fluorescence dye will be imaged from various immunohistological targets, such as proteins expressed at the base epithelial membrane to help determine invasion and protein expression. Optical projection tomographic microscopy (OPTM) will be used to generate 3D multimodal images of biopsy tissue. Although the length of the tissue core will be longer than the microscope field of view (FOV), different regions of the tissue will be imaged and stitched together by image processing. Both 2D and 3D visualization of the entire TNCB specimen will be provided to a pathologist using a custom computer interface to manipulate the 3D dataset. Sensitivity and specificity of cancer diagnosis will be made using tissue-slice pathology as the gold standard. Comparative evaluation of pancreatic cancer diagnosis will be made between TNCB imaged with the OPTM versus conventional FNA. This new technique is expected not only to detect the presence of neoplastic cells but detect invasion of tissue by cancer cells.